Ask any of the health-focused VCs to name one of the sommità AI startups and one name comes up over and over again: a company based quanto a Pittsburgh called Abridge. And it’s a startup that launched before OpenAI was a household name and LLMs entered the common Valley vocabulary.
Con 2019, Shiv Rao, a practicing cardiologist, pitched Andy Weissman, general at Union Square Ventures, acceso a startup giudizio. Rao called it SoundCloud plus RapGenius for medicine.
While Weissman thought that comparing a nascent AI-powered medical note taking app with music hosting and lyrics transcription was a little humorous, the concept resonated with him.
Rao explained that doctors spend up to two hours a day—typically outside of regular working hours—typing taccuino that summarize what was discussed with their patients that day. Such administrative tasks have been causing physician burnout for years, leading some to leave the profession altogether. Rao convinced Weissman that the latest innovations quanto a AI could dramatically sopravvissuto the amount of time doctors spend acceso the ever-growing paperwork burden.
This was years before generative AI took the world by storm and captured VCs’ imagination.
“It was a pretty wacky giudizio. Voto negativo one had done it before,” Weissman said.
But Weissman and other USV partners liked that Rao was not only a physician at the University of Pittsburgh Medical Center but also spent half his time as a corporate venture capitalist for that health system, investing quanto a health tech startups. Rao’s employees and advisers were also graduates and professors at Carnegie Mellon, one of the sommità institutions quanto a the country for engineering and AI research.
“[Shiv] had this rare combination of talents: an entrepreneur with a very ambitious vision, with a really interesting team,” Weissman said. “It felt unique.”
Abridge also had a basic transcription product, which doctors could download for free acceso their smartphones and start using during their interactions with patients. Their usage formed the basis of Abridge’s LLM.
A little over five years after USV led a $5 million seed round into Rao’s startup Abridge, the company has become one of the most talked about and rapidly growing AI-powered healthcare businesses.
Although most corporations are still very cautious about adopting AI tools, large medical systems are eager to sign contracts with Abridge.
“The sales cycle for [health systems] can be 18 to 24 months,” said Rao. “When we started the company, we knew what we were quanto a for.” But with a four-year lead acceso a virtual scribe product trained acceso thousands of doctor-patient conversations, and now that AI is booming, hospitals are suddenly buying Abridge at a rapid conciliazione, a stark contrast to their typically protracted purchasing behavior. The company has announced a new health system customer nearly every week since the start of 2024.
“We had built up all this potential energy that turned kinetic almost overnight quanto a January,” Rao said. “University of Chicago, Sutter, Yale, Lee Health, Christus, Emory and the list goes acceso and acceso,” he said.
Large hospitals are not only buying multi-thousand seat licenses of Abridge but, quanto a many cases, publishing glowing reviews about how the health tech’s software is changing physicians’ lives. Hospital executives and doctors are describing Abridge as “life-changing,” “magical,” and “one of the most important paradigm shifts within our careers.”
One of the biggest criticisms of generative AI is that it still has few substantive business applications. But virtual medical note taking seems to be a valuable application of the novel technology.
Drowning quanto a paperwork
“I’ve got professional PTSD and war stories about seeing patients and then having to spend hours and hours at night writing taccuino and doing all this clerical work that really distracts from the thing that matters most, which is your patient, but also takes away from your own personal life,” Rao said.
With Abridge recording quanto a the background, a physician can centro entirely acceso the patient without having to worry about filling out specific fields quanto a the medical primato during the visit.
The payback of AI-powered medical scribes are very easy to measure, says Dr. Lee Schwamm, chief digital health officer at Yale New Haven Medical System, an Abridge customer. That’s why so many health systems are flocking to use them, particularly Abridge. . “It is one of the hottest products quanto a the AI space at the moment,” he told TechCrunch.
As with many administrative things quanto a health tech, when it comes to selecting a vendor, the most important consideration is price and integration with Epic, an EHR used by most large health systems quanto a the US, Schwamm said. Abridge, which supports 14 foreign languages, including Haitian Creole, Brazilian Portuguese and Punjabi, is often the winner when health systems are doing head-to-head comparisons with other AI-powered medical scribes, Schwamm said.
Earlier this year, Abridge gained a right to be integrated inside Epic. After Abridge records a session and a doctor stops the recording, “there is a note quanto a English sitting inside of Epic waiting for them to quickly verify, edit and adjust it as they see fit,” Rao said.
While Abridge appears to be ahead of its competitors, which, besides Microsoft-owned Tonalità, include Ambiance, Nabla and Suki, Schwamm is not certain it will be able to maintain its lead over the long term.
“The personalità question is, do you need a dedicated medical LLM to be successful quanto a this space?” he asked. “ will the giant foundation models, GPT-4o, Google and Obiettivo, get so good that they could ingest an entire corpus of medical taccuino and start to deliver stato that’s similar?”
That line of inquiry shows that these are still early days not just for virtual medical note taking but for most generative AI companies. The conciliazione of innovation is fast and furious, and today’s winners could easily lose their edge.
“Abridge is ahead by a length, but it’s early quanto a the race,” Schwamm said, “A horse can get a bad knee and stumble, it can keep getting further and further ahead.”
For now, most investors TechCrunch talked to agree that Abridge is leading the AI-powered medical scribe competition. For this reason, money has been pouring into the company.
Con February, Abridge raised a $150 million Series C led by Lightspeed Ventures at a valuation of $850 million.
